Your browser doesn't support javascript.
loading
An updated review of epidemiological characteristics, immune escape, and therapeutic advances of SARS-CoV-2 Omicron XBB.1.5 and other mutants.
Liu, Zongming; Li, Jiaxuan; Pei, Shanshan; Lu, Ying; Li, Chaonan; Zhu, Jiajie; Chen, Ruyi; Wang, Di; Sun, Jingbo; Chen, Keda.
Afiliação
  • Liu Z; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Li J; Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Pei S; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Lu Y; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Li C; School of Pharmacy, Beihua University, Jilin, China.
  • Zhu J; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Chen R; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Wang D; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Sun J; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Chen K; Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Front Cell Infect Microbiol ; 13: 1297078, 2023.
Article em En | MEDLINE | ID: mdl-38156316
ABSTRACT
The rapid evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to the emergence of new variants with different genetic profiles, with important implications for public health. The continued emergence of new variants with unique genetic features and potential changes in biological properties poses significant challenges to public health strategies, vaccine development, and therapeutic interventions. Omicron variants have attracted particular attention due to their rapid spread and numerous mutations in key viral proteins. This review aims to provide an updated and comprehensive assessment of the epidemiological characteristics, immune escape potential, and therapeutic advances of the SARS-CoV-2 Omicron XBB.1.5 variant, as well as other variants.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article